4 With Upcoming Ex-Dividend Dates: PDLI, WRI, CTB, HD

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Tuesday, Sept. 3, 2013, 11 U.S. common stocks are scheduled to go ex-dividend. The dividend yields on these stocks range from 0.4% to 9.5%. All of these stocks can be found on our stocks going ex-dividend section of our dividend calendar.

Highlighted Stocks Going Ex-Dividend Tuesday:

PDL BioPharma

Owners of PDL BioPharma (NASDAQ: PDLI) shares as of market close today will be eligible for a dividend of 15 cents per share. At a price of $7.91 as of 9:35 a.m. ET, the dividend yield is 7.5%.

The average volume for PDL BioPharma has been 1.9 million shares per day over the past 30 days. PDL BioPharma has a market cap of $1.1 billion and is part of the drugs industry. Shares are up 13% year to date as of the close of trading on Thursday.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

PDL BioPharma, Inc. engages in intellectual property asset management and patent portfolio and related assets investment activities. The company has a P/E ratio of 4.94.

TheStreet Ratings rates PDL BioPharma as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, impressive record of earnings per share growth, compelling growth in net income, good cash flow from operations and expanding profit margins. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. You can view the full PDL BioPharma Ratings Report now.

If you liked this article you might like

Sarepta Pops on Bullish Sentiment Around Duchenne Therapy, PDL Up on Merck Deal: Biotech Movers

Argos Plummets 72%, Leads Biotech Movers

Eli Lilly's Alzheimer's Drug Study Results Are Coming -- Here's What Investors Need to Know

PDL BioPharma (PDLI) Stock Plummets on Q2 Revenue Miss

Today's Weak On High Volume Stock: PDL BioPharma (PDLI)